Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PCK1 | P35558 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167640 | 0.95 | ADORA2B (0.43) | ADORA2BADORA2ATSHRADORA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4174151 | 0.95 | ADORA2B (0.42) | ADORA2BADORA2ATSHRADORA1SMN1; SMN2 | |
| SCHEMBL1334379 | 0.94 | TSHR (0.40) | ADORA2BADORA2ATSHRADORA1L3MBTL1 | |
| SCHEMBL1332404 | 0.91 | ADORA2B (0.44) | ADORA2BADORA2ATSHRADORA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1332577 | 0.91 | ADORA2B (0.43) | ADORA2BADORA2ATSHRADORA1SMN1; SMN2 | |
| SCHEMBL1332403 | 0.90 | ADORA2B (0.41) | ADORA2BADORA2ATSHRADORA1KMT2A | |
| SCHEMBL1334371 | 0.90 | TSHR (0.40) | ADORA2BADORA2ATSHRADORA1KMT2A | |
| SCHEMBL4176276 | 0.90 | ADORA2B (0.43) | ADORA2BADORA2ATSHRADORA1KMT2A | |
| SCHEMBL1332410 | 0.89 | ADORA2B (0.41) | ADORA2BADORA2ATSHRADORA1KMT2A | |
| SCHEMBL1334268 | 0.89 | ADORA2B (0.36) | ADORA2BADORA2ATSHRADORA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2009-03-12 | — | — | US | claimed |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2007-11-29 | — | — | US | claimed |
| EP-1636230-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2004110379-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2004-12-23 | — | — | WO | claimed |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1636230-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110379-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | HRH3, HRH1, HRH2 | ADORA2B 9/4885ADORA2A 7/4885TSHR 1275/4885 |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ADORA1, ADORA3, ADORA2A | ADORA2B 4/4885ADORA2A 3/4885TSHR 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.